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± 13,682 versus 567,920 ± 15,127), leading to an incremental
cost-effectiveness ratio of SEK 4373 per QALY gained for IAsp
versus HSI. From a societal perspective, IAsp was life and cost
saving (dominant) compared to HSI, assuming that workplace
productivity improved with diabetes-related complications
avoided. CONCLUSIONS: Over patient lifetimes, IAsp was pro-
jected to improve LE and QALE and reduce the cumulative inci-
dence of diabetes-related complications, with cost savings from
a societal perspective in Sweden, compared to HSI.
PDB11
LONG-TERM COST-EFFECTIVENESS ANALYSIS OF
REPAGLINIDE VERSUS NATEGLINIDE IN COMBINATION
WITH METFORMIN IN TYPE 2 DIABETES PATIENTS FAILING
MONOTHERAPY IN THE SWEDISH SETTING
Ray J1, Brandt AS2, Foos V1, Munro V3,Valentine WJ1, Roze S1,
Palmer AJ1
1CORE—Center for Outcomes Research, A Unit of IMS, Allschwil,
Basel, Switzerland, 2Novo Nordisk Scandinavia AB, Malmo, Sweden,
3Novo Nordisk Ltd, Crawley, West Sussex, UK
OBJECTIVES: To estimate the long-term clinical and economic
outcomes associated with repaglinide or nateglinide therapy,
both in combination with metformin, in patients with type 2 dia-
betes inadequately controlled with sulfonylurea or metformin
monotherapy, or with low dose glybenclamide plus metformin
in the Swedish setting. Based on the results of a recent 16-week
clinical trial. METHODS: A published and validated, interactive
computer model was adapted to project life expectancy (LE),
quality-adjusted life expectancy (QALE), cumulative incidence of
complications and costs in the Swedish setting. The model com-
prises a series of Markov sub-models that simulate the long-term
incidence and progression of diabetes-related complications
based on published data. Baseline cohort characteristics (mean
age 55.8 years, duration of diabetes 7 years, HbA1c 8.4%, BMI
33 kg.m-2) and intervention effects were derived from the clini-
cal trial. Costs were accounted from a societal perspective (treat-
ment, complication and lost-productivity costs) and expressed in
year 2005 Swedish Kronor (SEK) values. Clinical and cost out-
comes were projected over a lifetime horizon and discounted at
3% per annum. RESULTS: Repaglinide + metformin was asso-
ciated with an increase in LE of 0.21 years (9.82 ± 0.18 versus
9.61 ± 0.17) and in QALE of 0.17 quality-adjusted life years
(6.34 ± 0.12 versus 6.17 ± 0.11) compared to nateglinide + met-
formin. There was a reduced cumulative incidence of diabetes-
related complications associated with repaglinide + metformin
treatment, most notably for retinopathy and nephropathy, com-
pared to nateglinide + meformin. Lifetime costs were lower for
repaglinide + metformin compared to nateglinide + metformin
from both a third party payer (SEK 337,897 ± 11,471 versus
SEK 380,867 ± 13,226) and societal perspective (SEK 629,525
± 22,446 versus SEK 647,635 ± 21,191). CONCLUSIONS:
Treatment with repaglinide + metformin was projected to be
associated with increased time free of diabetes-related complica-
tions and dominant (cost and life saving) from a societal per-
spective, compared to nateglinide + metformin, in the Swedish
setting.
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OBJECTIVES: To project the long-term clinical and economic
outcomes associated with continuous subcutaneous insulin 
infusion (CSII) compared with multiple daily injection (MDI) 
in patients with type 1 diabetes in Sweden and Norway.
METHODS: A previously published and validated computer
simulation model of type 1 diabetes was adapted to project life
expectancy (LE), quality-adjusted life expectancy (QALE) and
costs in Norwegian and Swedish settings. Effects associated with
CSII and MDI delivery systems and baseline simulated cohort
characteristics (mean age 26 years, duration of diabetes 12 years,
54% male, mean HbA1c 8.68%) were taken from a recent meta-
analysis. Direct medical costs and indirect costs (human capital
approach) were accounted in year 2005 values. Clinical and cost
outcomes were projected over a lifetime horizon and discounted
at a rate of 3% per annum. RESULTS: CSII treatment was 
associated with increased LE versus MDI in the Norwegian 
and Swedish settings (0.95 and 1.03 years, respectively) and
increased QALE (0.98 and 1.03 quality-adjusted life years
(QALYs), respectively). The cumulative incidence of diabetes-
related complications, particularly nephropathy and retinopathy
complications was also lower in the CSII treatment arm com-
pared to MDI. Mean lifetime costs were greater for CSII treat-
ment compared to MDI in the Norwegian setting (NOK
3,505,368 ± 77,645 versus 3,480,974 ± 76,698), which pro-
duced an incremental cost-effectiveness ratio (ICER) of NOK
24,837 (∼€3200) per QALY gained for CSII versus MDI. In the
Swedish setting CSII was also associated with higher lifetime
costs compared to MDI (SEK 3,026,056 ± 58,873 vs 2,965,366
± 60,025) which led to an ICER of SEK 58,830 (∼€6300) per
QALY gained for CSII versus MDI. CONCLUSIONS: CSII was
associated with increased LE and QALE and reduced incidence
of diabetes-related complications compared to MDI. CSII repre-
sents good value for money in the Norwegian and Swedish
setting from a societal perspective by generally accepted 
standards.
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OBJECTIVES: The purpose of this study was to evaluate the rel-
ative cost effectiveness (cost utility) of insulin glargine versus
NPH insulin in the UK for the treatment of people with type 2
diabetes mellitus (T2DM) using pooled data from the Phase III
clinical trials programme. METHODS: This was a health eco-
nomic evaluation using a stochastic simulation model. Transition
probabilities for progression to diabetes-related complications
for the model were derived mainly from the UKPDS (UK
Prospective Diabetes Study) risk equations. Costs were derived
from published estimates and local data. The maximum time
horizon was 40 years to ensure effective modelling of diabetes
